Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
MicroRNAs (miRs, miRNAs) are regulatory small noncoding RNAs, with their roles already confirmed to be important for post-transcriptional regulation of gene expression affecting cell physiology and disease development. Upregulation of a cancer-causing miRNA, known as oncogenic miRNA, has been found in many types of cancers and, therefore, represents a potential new class of targets for therapeutic inhibition. Several strategies have been developed in recent years to inhibit oncogenic miRNAs. Among them is a direct approach that targets mature oncogenic miRNA with an antisense sequence known as antimiR, which could be an oligonucleotide or miRNA sponge. In contrast, an indirect approach is to block the biogenesis of miRNA by genome editing using the CRISPR/Cas9 system or a small molecule inhibitor. The development of these inhibitors is straightforward but involves significant scientific and therapeutic challenges that need to be resolved. In this review, we summarize recent relevant studies on the development of miRNA inhibitors against cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Predicting effective microRNA target sites in mammalian mRNAs
Agarwal, V., Bell, G. W., Nam, J.-W., & Bartel, D. P. (2015) · eLife · doi:10.7554/elife.05005 · Cited by 7,318 · cited 2×
“Sci. 2018, 19, 65; doi:10.3390/ijms19010065 www.mdpi.com/journal/ijms To date, a huge number of miRNAs has been found and this information is stored in several miRNA databases such as miRbase [8], microRNA [9], or TargetScan [10].”
BackgroundInfluentialRegulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332 · cited 1×
“Another class of DNA mimic compounds is named peptide nucleic acids (PNAs) [70] and is an effective artificial agent for targeting miRNA.”
BackgroundMicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06174 · Cited by 2,605
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272 · cited 1×
“miR-106b/93 PTEN/Akt pathway Breast cancer [33] miR-125b P53 Lung cancer [34] miR-130a CRMP4 Gastric cancer [35] miR-155 SHIP1, PI3K, FADD, CDX1, C/EBPβ B-cell cancers, glioma [36–40] miR-181a PRKCD, Bim Cervical, breast cancer [41,42] miR-200s ZEB1, ZEB2, SIP1 Breast, ovarian cancer [43,44] miR-210-3p SOCS1, TNIP1, N…”
Tili, E., Michaille, J.-J., Cimino, A., Costinean, S., Dumitru, C. D., Adair, B., Fabbri, M., Alder, H., Liu, C. G., Calin, G. A., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5082 · Cited by 1,304 · cited 1×
“which encode a death domain, have been identified as target genes of miR-155, and the targeting of these transcripts may lead to antiapoptotic effects [38].”
BackgroundCas9 as a versatile tool for engineering biology
Mali, P., Esvelt, K. M., & Church, G. M. (2013) · Nature Methods · doi:10.1038/nmeth.2649 · Cited by 1,197
Inositol phosphatase SHIP1 is a primary target of miR-155
O'Connell, R. M., Chaudhuri, A. A., Rao, D. S., & Baltimore, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902636106 · Cited by 826
MicroRNA sponges: Progress and possibilities
Ebert, M. S., & Sharp, P. A. (2010) · RNA · doi:10.1261/rna.2414110 · Cited by 762 · cited 1×
“It was initially introduced in 2007 [90] and achieved stable inhibition of miRNAs in cancer cells, as well as in transgenic animals [91].”
BackgroundLNA (Locked Nucleic Acid): High-Affinity Targeting of Complementary RNA and DNA
Vester, B., & Wengel, J. (2004) · Biochemistry · doi:10.1021/bi0485732 · Cited by 727 · cited 1×
“For this reason, it became a promising choice for targeting miRNAs by antisense-based gene silencing [58,62].”
BackgroundRegulatory mechanisms of microRNA expression
Gulyaeva, L. F., & Kushlinskiy, N. E. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0893-x · Cited by 464 · cited 2×
“Known as ster regulators in the cell, miRNAs are involved in almost all the cellular p ocesses in both normal and pathological conditions including differentiation, proliferation, and migration [11,12].”
BackgroundRegulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers
Zhang, X., Gee, H., Rose, B., Lee, C. S., Clark, J., Elliott, M., Gamble, J. R., Cairns, M. J., Harris, A., Khoury, S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2109-4 · Cited by 65 · cited 3×
“The data showed that disruption of pre-miR-21 leads to upregulation of miR-21 target genes, PDCD4 and SPRY2.”
BackgroundNedaeinia, R., Sharifi, M., Avan, A., Kazemi, M., Nabinejad, A., Ferns, G. A., Ghayour-Mobarhan, M., & Salehi, R. (2017) · Tumor Biology · doi:10.1177/1010428317692261 · Cited by 47
Cited by
An overview of microRNAs: Biology, functions, therapeutics, and analysis methods
Saliminejad, K., Khorram Khorshid, H. R., Soleymani Fard, S., & Ghaffari, S. H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27486 · Cited by 1,872
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A.-M. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 291
Interplay between miRNAs and host genes and their role in cancer
Liu, B., Shyr, Y., Cai, J., & Liu, Q. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz002 · Cited by 137
Telomeres and telomerase in oncogenesis (Review)
Trybek, T., Kowalik, A., Góźdź, S., & Kowalska, A. (2020) · Oncology Letters · doi:10.3892/ol.2020.11659 · Cited by 119
miRNAs as therapeutic tools and biomarkers for prostate cancer
Arrighetti, N., & Beretta, G. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030380 · Cited by 43
Metadata
- Authors
- Nguyen, D.-D., & Chang, S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-12-27
- Volume
- 19
- Issue
- 1
- Pages
- 65
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2786455820
- Cited by
- 90
- References
- 14
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.